Clinical trials: Prophylaxis of Venous Thromboembolism
Total Knee Replacement Surgery
Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery
The purpose of this study is to evaluate the safety and efficacy of a single administration of TB-402 for the prevention of VTE in patients undergoing knee replacement surgery.
- Trial name
- NCT00793234
- Testing
- TB-402, Enoxaparin
- Where
- 35 sites in Bulgaria, Israel and 5 more
- Volunteers
- 316 people
- Sponsor
- ThromboGenics
TBI (Traumatic Brain Injury), VTE (Venous Thromboembolism)
Timing of VTE Prophylaxis in TBI
This study compares the efficacy and complication rates of early (24 hours) versus late (72 hours) VTE prophylaxis administration to TBI patients.
- Trial name
- NCT03081169
- Testing
- Enoxaparin Sodium 150 MG/ML Prefilled Syringe, Heparin
- Where
- United States
- Sponsor
- Loyola University
Multiple Myeloma, Venous Thromboembolism
Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.
Patients with newly diagnosed symptomatic multiple myeloma per IMWG criteria prior to therapy initiation are enrolled in the study.
- Trial name
- ROADMAP-MM (NCT03405571)
- Testing
- No intervention
- Where
- Greece
- Volunteers
- 800 people
- Sponsor
- University of Athens
Venous Thromboembolism
Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty
The purpose of this study is to compare the efficacy of two prophylactic agent(aspirin 300mg/day and rivaroxaban 10mg/day) for venous thromboembolism after total knee arthroplasty.
- Trial name
- NCT02271399
- Testing
- acetylsalicylic acid, rivaroxaban
- Where
- South Korea
- Volunteers
- 156 people
- Sponsor
- Hanyang University Seoul Hospital
Venous Thromboembolism
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
The primary efficacy objective is to evaluate whether dabigatran etexilate is superior to placebo in the long-term prevention of recurrent symptomatic venous thrombo-embolism (VTE) in patients with symptomatic deep-vein…
- Trial name
- RE-SONATE (NCT00558259)
- Testing
- dabigatran etexilate 150 mg twice daily (BID)
- Where
- 147 sites in United States, Australia and 19 more
- Volunteers
- 1,353 people
- Sponsor
- Boehringer Ingelheim
Venous Thrombosis, Pulmonary Embolism
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur within patients hospitalized for acute medical illness, and…
- Trial name
- ADOPT (NCT00457002)
- Testing
- Apixaban, Enoxaparin
- Where
- 296 sites in United States, Argentina and 33 more
- Volunteers
- 6,758 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism
Efficacy of Sodium Heparin in Prophylaxis of Venous Thromboembolism in Surgical Patients
The Venous thromboembolism (VTE) disease is very frequent, mainly as complications of medical diseases and surgical procedures. It has high prevalence and can lead to severe complications such as pulmonary embolism and…
- Trial name
- NCT00912483
- Testing
- heparin sodium - Blausiegel, Heparin sodium - APP
- Volunteers
- healthy volunteers welcome
- Sponsor
- Azidus Brasil
Neoplasms Malignant, Surgery
Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery
This is a prospective, twin-center, cohort study in patients discharged from the hospital after major abdominal or pelvic cancer surgery for cancer.
- Conditions
- Neoplasms Malignant, Surgery, Venous Thromboembolism, Prophylaxis
- Trial name
- NCT04479579
- Testing
- Apixaban 2.5 milligram
- Where
- 2 sites in Canada
- Volunteers
- 53 people
- Sponsor
- McMaster University
Venous Thromboembolism
Retrospective Study to Review Patients at Risk for VTE at Hospital Discharge
An investigator initiated study exploring VTE prophylaxis at the time of hospital discharge.
- Trial name
- NCT00604370
- Volunteers
- 2,500 people
- Sponsor
- Brigham and Women's Hospital
Venous Thromboembolism, Pulmonary Embolism
Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage
The objective of this randomized clinical trial is to evaluate the safety and efficiency of different anticoagulation schemes with heparin for venous thromboembolism prevention in patients with hypertensive intracerebral…
- Conditions
- Venous Thromboembolism, Pulmonary Embolism, Intracerebral Hemorrhage, Deep Vein Thrombosis
- Trial name
- NCT06753786
- Testing
- Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting within the first 2 days but not earlier than 12 hours after a hospital admission., Venous thromboembolism prophylaxis with unfractionated heparin or low molecular weight heparin starting on the 3rd day after a hospital admission.
- Where
- Russia
- Volunteers
- 200 people
- Sponsor
- Pirogov Russian National Research Medical University
Venous Thromboembolism
Computerized Decision Support for Prevention of VTE in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT)
Hospitalized medical patients have an increased risk of venous thromboembolism (VTE) across the continuum of care, including after hospital discharge.
- Trial name
- DC-eALERT (NCT03728166)
- Testing
- Electronic alert
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Venous Thrombosis (Disorder)
Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of VTE Prophylaxis
VTE associated harm is underappreciated among hospitalized patients and may be associated with missed doses of VTE prophylaxis medications.
- Trial name
- ENACT (NCT03367364)
- Testing
- Patient education bundle (PEB),, Nurse feedback and coaching (NFC)
- Where
- United States
- Volunteers
- 9,657 people
- Sponsor
- Johns Hopkins University
Venous Thromboembolism
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
Rationale: After total knee arthroplasty (TKA) surgery, patients are at risk to develop venous thromboembolism (VTE) or deep venous thrombosis (DVT) potentially resulting in a fatal pulmonary embolism (PE).
- Trial name
- DARINA (NCT01431456)
- Testing
- Dabigatran, Rivaroxaban, Nadroparin
- Where
- Netherlands
- Volunteers
- 148 people
- Sponsor
- Martini Hospital Groningen
Venous Thromboembolism
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'.
- Trial name
- ROXI-CATH (NCT06299111)
- Testing
- REGN9933, REGN7508
- Where
- 23 sites in United States, Bulgaria and 4 more
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer
Deep Venous Thromboses, Laparotomy Patients
Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention
The goal of this clinical trial is to learn if rivaroxaban works better than enoxaparin to prevent deep vein thrombosis (DVT) after emergency exploratory laparotomy in adults.
- Trial name
- NCT07243080
- Testing
- rivaroxaban (10mg), Enoxaparin 40 mg SC
- Where
- Pakistan
- Volunteers
- 212 people
- Sponsor
- Mayo Hospital Lahore
Venous Thromboembolism
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
The objective of this study is to evaluate the safety and efficacy of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective hip fracture surgery.
- Trial name
- NCT01181141
- Testing
- DU-176b (edoxaban), Enoxaparin sodium 20mg
- Where
- Japan
- Volunteers
- 92 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Nephrotic Syndrome
Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome.
The primary objective is to test the hypothesis that enoxaparin efficacy is reduced in severe nephrotic syndrome. Another purpose is to compare two dosing regimens.
- Trial name
- ENOX-inNS (NCT04558892)
- Testing
- Enoxaparin
- Where
- Poland
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Military Institute od Medicine National Research Institute
Critical Illness, Therapeutic Drug Monitoring
Anti-Xa Level With Thromboprophylactic Dosage Nadroparin in Critically Ill COVID-19 and Non-COVID-19 Patients
Primary objective The objective of this study is to compare anti-Xa levels obtained with a standard high dose thrombosis prophylaxis in COVID-19 intensive care-patients compared with anti-Xa levels obtained with a normal dose…
- Conditions
- Critical Illness, Therapeutic Drug Monitoring, Venous Thromboembolism
- Trial name
- NADRO (NCT05926518)
- Testing
- blood sampling
- Where
- Netherlands
- Volunteers
- 62 people
- Sponsor
- Rijnstate Hospital
Venous Thromboembolism
A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery
The purpose of the study is to evaluate the efficacy and safety of the oral dose of YM150 for prevention of venous thromboembolism (VTE) in patients undergoing major abdominal surgery.
- Trial name
- NCT00942435
- Testing
- YM150, mechanical prophylaxis
- Where
- 6 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Astellas Pharma Inc